Navigation Links
Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development
Date:3/23/2010

-- Part of larger effort to develop and distribute high-quality experimental tools that will speed progress toward better treatments for PD --

NEW YORK, March 23 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation announced that monoclonal LRRK2 antibodies, for use in understanding LRRK2 function and developing LRRK2-based therapeutics, will be available to Parkinson's researchers in academic/nonprofit and industry labs. In mid-April, the antibodies will be available free of charge to the entire PD research community for experimental use. This will allow researchers to undertake large-scale testing of the antibodies and provide feedback on their performance directly to MJFF. Once the best-performing antibodies have been identified, the Foundation will determine a practical distribution mechanism to make them available to the research community going forward.

"Our mission is to accelerate next-generation Parkinson's therapies on their path toward the clinic, and it is impossible to overstate access to high-quality, reliable experimental tools as a critical element of this push," said Katie Hood, CEO. "One of our top priorities is to mobilize financial and intellectual leadership around the creation of research tools and get them into scientists' hands to keep promising therapeutic strategies moving forward full-speed ahead."

The Foundation's ongoing investment in critical research tools is made possible through the generous support of The Brin Wojcicki Foundation.

About LRRK2 and LRRK2 Antibodies

LRRK2 is a Parkinson's-implicated gene discovered in 2004 that is now believed to be the single greatest genetic contributor to the disease. While it is the focus of intensive research in the Parkinson's field, a major roadblock to the successful development of LRRK2-based therapies is the lack of high-quality LRRK2 antibodies. Antibodies are used by researchers to identify where proteins can be found in the body, how they behave in cells, and how to manipulate their activity. Despite numerous attempts by individual researchers, high-quality LRRK2 antibodies are rare and often difficult for labs to obtain.

In 2009 MJFF convened a LRRK2 Antibodies Working Group composed of academic and industry researchers with specific expertise in LRRK2. At the recommendation of this group, MJFF engaged a company specializing in antibody development, Epitomics, Inc., to generate several highly sensitive and specific LRRK2 antibodies in large amounts.

The LRRK2 antibodies project is part of MJFF's broadly integrated strategy to drive LRRK2 research at every stage of drug development and accelerate the path of LRRK2-based drugs to the clinic.

How to Obtain Antibodies

For detailed scientific information on the LRRK2 antibodies and information on how to obtain them, researchers should visit PD Online Research (pdonlineresearch.org) or the new Research Tools page located on the Foundation's Web site (michaeljfox.org/research).

Next Focus Area under MJFF's Research Tools Effort: Pre-clinical Models

In addition to the antibodies announced today, the Foundation is working to develop and create distribution channels for new pre-clinical models of Parkinson's that better mimic the human condition. Multiple strains of new models are expected to come online for distribution over the course of 2010. There is an urgent need for such models, particularly for the development of treatments that could slow or stop the progression of PD (something no current treatment has been conclusively proven to do). The Michael J. Fox Foundation has been a field leader in the development of PD models for several years, with investments totaling approximately $13 million to date.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $175 million in research to date. 

SOURCE Michael J. Fox Foundation

Back to top

RELATED LINKS
http://michaeljfox.org/research.cfm
http://www.pdonlineresearch.org/

'/>"/>

SOURCE Michael J. Fox Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
2. Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant
3. Oxford BioTherapeutics Appoints Michael Moore as Chairman
4. The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinsons Disease Treatments
5. Double Helix Consulting Enhances its Strategic Product Commercialization Services with Appointment of Michael Rizzo as Vice President
6. Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research
7. Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section
8. BioStorage Technologies, Inc., Welcomes Catherine Michael as Global Head of Sample Management Operations
9. Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
10. Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific Officer of Global Bioanalytical Services
11. Statement From Michael Hansen, CEO of Elseviers Health Sciences Division, Regarding Australia Based Sponsored Journal Practices Between 2000 and 2005
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... A new ... rates in frozen and fresh in vitro fertilization (IVF) transfer cycles. ... to IVF success. , After comparing the results from the fresh and frozen ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... -- International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... market and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase ... "The residential security market has experienced continued growth, ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee is ... honoring scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. ... world’s leading conference and exposition for laboratory science, which will be held February ...
Breaking Biology Technology:
(Date:8/23/2017)... , Aug. 23, 2017  The general public,s help is being ... microbiome—the bacteria that live in and on the human body –and are ... The Microbiome ... the human microbiome, starting with the gut. The project's goal is to ... Photo credit: IBM ...
(Date:7/20/2017)... July 20, 2017 Delta (NYSE: DAL ) customers ... Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft ... Delta,s biometric boarding pass ... is now integrated into the boarding process to allow eligible Delta ...
(Date:6/23/2017)... and ITHACA, N.Y. , June ... Cornell University, a leader in dairy research, today announced ... designed to help reduce the chances that the global ... onset of this dairy project, Cornell University has become ... Sequencing the Food Supply Chain, a food safety initiative ...
Breaking Biology News(10 mins):